Press release
The NF1-PN Market in 7MM to Witness Notable Growth, Expanding from USD 380 million in 2023 | DelveInsight
The Neurofibromatosis type 1-associated Plexiform Neurofibromas market across the 7MM is expected to surge owing to an increased awareness, advancements in diagnostic techniques, greater accessibility to genetic testing, and the emergence of new transformative treatments such as KOSELUGO (AstraZeneca and Merck), Mirdametinib (SpringWorks Therapeutics), HLX-1502 (Healx), FCN-159 (Fosun Pharmaceutical), and AS-004 (Pasithea Therapeutics).
DelveInsight's report titled "Neurofibromatosis Type 1-associated Plexiform Neurofibromas (NF1-PN): Market Insights, Epidemiology, and Market Forecast - 2034 [https://www.delveinsight.com/report-store/neurofibromatosis-type1-associated-plexiform-neurofibromas-nf-pn-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" offers comprehensive epidemiological data along with insights into market trends, an analysis of the competitive landscape, current and emerging therapeutic approaches, and assessments of the patient journey concerning NF1-PN, a rare disease.
The report forecasts that the NF1-PN market across the 7MM, which includes the United States, the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan, will grow from ~USD 380 million in 2023 at a considerable CAGR by 2034. This anticipated growth is attributed to ongoing research into the genetic underpinnings of these tumors, the availability of medical therapy as an alternative to surgery, improvements in administration ease, and a decrease in side effect profiles of emerging therapies.
According to the report, the United States consistently holds the highest market share among the 7MM, with around USD 230 million in 2023.
The report provides a detailed epidemiological analysis and forecasts up to 2034, segmented by total NF1 diagnosed prevalent cases, diagnosed cases of NF1 manifestations, age-specific NF1-PN diagnosed cases, NF1-PN cases by clinical symptoms, and NF1-PN cases eligible for surgery in the 7MM. In 2023, the majority of diagnosed NF1-PN patients were estimated to be in the US, followed by Germany.
Current NF1-PN treatment practices, emerging drugs, market shares of individual therapies, and unmet medical needs from 2020 to 2034 are also addressed in the report. While surgery remains a standard treatment for many patients, it is often complex, not always feasible, carries inherent risks, and has a high possibility of tumor recurrence. A multidisciplinary approach involving genetics, neurology, radiology, and surgery, is vital for effectively managing the disease's physical and emotional impacts.
With an improved understanding of the genetic basis of plexiform neurofibromas, targeted therapies like the MEK inhibitor KOSELUGO (AstraZeneca and Merck) have emerged as promising options, especially for pediatric patients with inoperable NF1-PN. Building on this progress, researchers are exploring other MEK inhibitors for potential use in both pediatric and adult patients.
The current NF1-PN developmental pipeline includes additional MEK inhibitors such as Mirdametinib (SpringWorks Therapeutics), FCN-159 (Fosun Pharmaceutical), and PAS-004 (Pasithea Therapeutics). Another emerging drug, HLX-1502 (Healx), offers a unique investigational treatment option for NF1 patients. In October 2024, the US FDA granted Fast Track Designation (FTD) to HLX-1502 for the treatment of NF1.
Recent developments include findings for PAS-004, which demonstrated no dose-limiting toxicities in Phase 1 clinical trials. An external Safety Review Committee recommended proceeding with its higher doses without modification in February 2025, highlighting the potential of these emerging therapies to revolutionize NF1-PN treatment.
Although NF1-PN presents significant challenges due to its highly individualized treatment needs-including multidisciplinary teamwork, tumor regrowth, and complications arising from tumors developing in critical areas like the head, neck, chest, or spine-the emergence of novel therapies as an alternative to surgery, improving administration ease and minimize side effects, is expected to broaden treatment options and enhance market growth.
Table of Contents
1.
KEY INSIGHTS
2.
REPORT INTRODUCTION
3.
EXECUTIVE SUMMARY OF NF1-PN
4.
EPIDEMIOLOGY AND MARKET METHODOLOGY
5.
NF1-PN MARKET OVERVIEW AT A GLANCE
6.
KEY EVENTS
7.
DISEASE BACKGROUND AND OVERVIEW
8.
EPIDEMIOLOGY AND PATIENT POPULATION
9.
PATIENT JOURNEY
10.
MARKETED DRUGS
11.
EMERGING DRUGS
12.
NF1-PN: SEVEN MAJOR MARKET ANALYSIS
13.
UNMET NEEDS
14.
SWOT ANALYSIS
15.
KOL VIEWS
16.
MARKET ACCESS AND REIMBURSEMENT
17.
APPENDIX
18.
DELVEINSIGHT CAPABILITIES
19.
DISCLAIMER
20.
ABOUT DELVEINSIGHT
Related Reports
Plexiform neurofibroma Pipeline Insight [https://www.delveinsight.com/report-store/plexiform-neurofibroma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
Plexiform neurofibroma Pipeline Insight provides comprehensive insights about the Plexiform neurofibroma pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Plexiform neurofibroma companies, including SpringWorks Therapeutics, Array BioPharma, Novartis, Shanghai Fosun Pharmaceutical Development Co, Ltd.,and Ashvattha Therapeutics, among others.
Plexiform Neurofibroma Market Insight [https://www.delveinsight.com/report-store/plexiform-neurofibroma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
Plexiform Neurofibroma Market Insight, Epidemiology And Market Forecast report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Plexiform Neurofibroma market trends, market drivers, market barriers, and key Plexiform Neurofibroma companies, including SpringWorks Therapeutics, Array BioPharma, Novartis, Shanghai Fosun Pharmaceutical Development Co, Ltd.,and Ashvattha Therapeutics, among others.
[https://www.delveinsight.com/report-store/plexiform-neurofibroma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
DelveInsight is a leading business Healthcare consultancy and market research firm specializing in life sciences. It assists pharmaceutical companies by offering comprehensive, end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=the-nf1pn-market-in-7mm-to-witness-notable-growth-expanding-from-usd-380-million-in-2023-delveinsight]
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release The NF1-PN Market in 7MM to Witness Notable Growth, Expanding from USD 380 million in 2023 | DelveInsight here
News-ID: 3904808 • Views: …
More Releases from ABNewswire
Intella Parts Company, LLC: Nine Things to Consider Owning a Forklift
Image: https://www.abnewswire.com/upload/2025/10/e03a895d79e86b26ca4286745366845c.jpg
Owning a forklift is a significant responsibility that goes beyond simply acquiring a piece of equipment. A forklift can dramatically improve productivity and efficiency in any warehouse, factory, or yard operation-but only when managed properly. It's a long-term investment that requires consistent maintenance, trained operators, and a commitment to safety and compliance. Neglecting these elements can quickly turn a forklift from an asset into a costly liability.
1. Define Your…
Bari Life Expands into Smart Activewear to Complete the Post-Surgery Wellness Ec …
Image: https://www.abnewswire.com/upload/2025/10/3a0fe022a8ed3074fcb17e0794a17eb7.jpg
In today's fast-paced world, wellness isn't just a trend, it's a lifestyle. As we strive for better health and performance, the idea of smart wellness shopping has become increasingly important. This approach combines technology and informed choices to help us find products that truly support our physical and mental well-being.
For instance, specialized supplements like the gastric bypass multivitamin [https://barilife.com/collections/bariatric-vitamins] are designed to meet the unique nutritional needs of those…
Scout by PipelineAI Launches as Singapores First AI Employee for Customer Outrea …
Built by 91 Branding & Marketing, Scout helps SMEs find and engage real customers through social media conversations - at a fraction of the cost of hiring.
Image: https://www.abnewswire.com/upload/2025/10/671df834c20b52315a9e22b6ec33ddd0.jpg
Singapore - 21 October, 2025 - 91 Branding & Marketing today announced the launch of Scout by PipelineAI [https://scout.ninetyone.sg/], an AI-powered customer outreach agent designed to help small and medium-sized enterprises (SMEs) discover and engage real customers through everyday social media conversations.
Unlike traditional…
Affordable Alternative to AirOps and Peec AI Launched by AI SEO Expert - Cairrot …
Cairrot, a cutting-edge AI visibility and optimization tool, has officially launched for marketers and agencies wishing to dominate AI search across tools like ChatGPT, Claude, Perplexity, Gemini, Deepseek, and Grok, but don't want to pay the price tag of alternatives like AirOps or Peec Ai. Founded by Connor Kimball, a seasoned SEO and AEO leader, Cairrot arose from a need to deliver results in AI search for clients that demanded…
More Releases for NF1
Neurofibromatosis Type 1-Associated Plexiform Neurofibromas (NF1-PN) Market Pois …
Neurofibromatosis Type 1-Associated Plexiform Neurofibromas (NF1-PN) Market Summary
NF1-PN Market Set to Grow Beyond USD 380 Million by 2034 driven by rising diagnosed cases, better awareness, advanced diagnostics, and genetic testing. In the US alone, ~97,000 diagnosed NF1 cases were reported in 2023, expected to increase by 2034. Treatment remains challenging-surgery is often complex, risky, and prone to recurrence, leaving significant unmet needs, especially in pediatric patients with inoperable PNs. Current…
Neurofibromatosis Type 1 Treatment Landscape: FDA Expands KOSELUGO Approval to Y …
DelveInsight Business Research's analysis underscores the transformative impact of the FDA's September 10, 2025 approval of KOSELUGO (selumetinib) granules and capsules for pediatric patients aged 1 year and older with symptomatic, inoperable plexiform neurofibromas (PN) associated with Neurofibromatosis Type 1 (NF1). This expansion marks the first therapy targeting NF1-PN in this younger age group, offering hope to ~97,000 diagnosed children in the US.
Key NF1 Market Highlights
*
The Neurofibromatosis Type 1 treatment…
Neurofibromatosis Type 1-Associated Plexiform Neurofibromas (NF1-PN) Market to R …
Neurofibromatosis type 1 (NF1) is a rare, genetic tumor predisposition disorder caused by mutations in the NF1 gene. Among its manifestations, plexiform neurofibromas (PNs) are one of the most severe complications. These benign but often disfiguring and painful tumors can cause neurological impairment, airway obstruction, spinal deformities, and malignant transformation in rare cases.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71719
Until recently, management relied on surgery, which is often…
Neurofibromatosis Type 1 (NF1) Market to Reach USD 2.5 Billion by 2034
Neurofibromatosis Type 1 (NF1) is one of the most common genetic disorders among rare diseases, affecting approximately 1 in 3,000 individuals worldwide. It is caused by mutations in the NF1 gene, which encodes neurofibromin, a protein that helps regulate cell growth. Patients with NF1 develop benign tumors along nerves, skin abnormalities, and in some cases, malignant peripheral nerve sheath tumors (MPNSTs).
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71663
Historically,…
The NF1-PN Market Size in 7MM to Witness Notable Growth, Expanding from USD 380 …
The the emergence of new transformative NF1-PN treatments such as KOSELUGO (AstraZeneca and Merck), Mirdametinib (SpringWorks Therapeutics), HLX-1502 (Healx), FCN-159 (Fosun Pharmaceutical), and AS-004 (Pasithea Therapeutics), and others.
The Neurofibromatosis type 1-associated Plexiform Neurofibromas market across the 7MM is expected to surge owing to an increased awareness, advancements in diagnostic techniques, greater accessibility to genetic testing, and the emergence of new transformative treatments such as KOSELUGO (AstraZeneca and Merck), Mirdametinib (SpringWorks…
In-Depth Analysis of the Neurofibromatosis Type 1 Market: Growth Opportunities, …
What industry-specific factors are fueling the growth of the neurofibromatosis type 1 market?
The rising occurrence of spontaneous (de novo) mutations is expected to boost the growth of the neurofibromatosis type 1 (NF1) market. Spontaneous mutations occur due to errors in DNA replication or environmental factors, rather than being inherited. In NF1, the high mutation rate in the NF1 gene contributes to new cases, even without a family history. For example,…
